Novogen soars as subsidiary hits the fast track
Friday, 05 November, 2004
Investors added more than AUD$1 -- or 20 per cent -- to Novogen's (ASX:NRT) share price today on the news that the company's subsidiary Marshall Edwards (Nasdaq: MSHL/LSE AIM:MSH) had been granted fast-track status for the use of phenoxodiol in recurrent ovarian cancer.
The US Food and Drug Administration grants fast track review status to drugs that could treat an unmet medical need, making them eligible for accelerated marketing approval.
"We are developing phenoxodiol for the treatment of a wide range of cancers, but for the purpose of this fast track program, we are focusing on its use as a chemo-sensitising agent in recurrent, late-stage ovarian cance," said Marshall Edwards executive chairman Dr Graham Kelly in a statement.
Marshall Edwards is currently putting phenoxodiol through Phase II clinical trials as a stand-alone therapy and in combination with other drugs for the treatment of a range of cancers.
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
Immune cell boost could enable lasting vaccine protection
A research team has found a promising new way to enhance the effectiveness of vaccines by tapping...
